ReviewFrontiers in pharmacology2025
Evaluation of natural products bioactivity in cardiovascular diseases utilizing zebrafish models: a comprehensive review.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N-International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are a major global health challenge, significantly impacting public health and healthcare systems. Ethnopharmacological remedies and botanical medicines are widely used for the prevention and treatment of CVDs due to their multi-component, multi-target properties. Understanding the mechanisms of these natural products is essential for developing safe and effective therapies. The zebrafish model, an emerging tool in experimental pharmacology, has been increasingly used to evaluate the pharmacological activities of natural products. This review focuses the use of zebrafish models to test the prevention and treatment effects of various CVDs, and to investigate the inhibition of hyperlipidemia, thrombosis, the progress of heart failure, and the promotion of angiogenesis and toxicity. Emphasizing its experimental advantages-including the transparency characteristics of the body, its applicability to the analysis of multiple samples, and its support for real-time monitoring-aims to reveal its potential value in combining traditional cognition with contemporary pharmacological testing capabilities. The literature summary provides strong evidence for the cognitive improvement of the zebrafish system in clarifying the efficacy of natural ingredients in the cardiovascular field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.